Generic Drug Market Growth: CAGR of 5.22% Forecasted Through 2032

The Global Market for Generic Drugs ,which was worth about USD 453.65 Bn. in 2024, is projected to exhibit a compound annual growth rate (CAGR) of 5.22% over the period 2025-2032. The growth is mainly attributed to the rising number of chronic diseases and cost-effective medications.

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐟𝐨𝐫 𝐟𝐫𝐞𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 + 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐠𝐫𝐚𝐩𝐡𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭:-https://www.stellarmr.com/report/req_sample/Generic-Drug-Market/1638

𝐊𝐞𝐲 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐎𝐟 𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 & 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

Increasing prevalence of chronic diseases like cardiovascular diseases, diabetes, and cancer, has significantly increased the demand for affordable treatment alternatives. Generic drugs have become a more favored choice by healthcare providers or patients as they are bioequivalent to their branded equivalents but are sold at lower prices.

Furthermore, several of the best-selling drugs' patents have expired, allowing for generic drug manufacturers to produce copies of drugs and advance into the market. Such a trend not only increases market competition, but also renders necessary drugs available for larger population.

Moreover, growing initiatives by governments to prescribe generic drugs combined with healthcare reforms focused on curbing medical costs contribute to the market. For example, the use of policies promoting generic substitution as well as faster approval timelines for generic drug applications have helped facilitate market entry for new players.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

On the basis of product type, application, and distribution channel the generic drug market is segmented.

𝐁𝐚𝐬𝐞𝐝 𝐨𝐧 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐭𝐲𝐩𝐞, the market for simple generics, super generics, and biosimilars. Although simple generics are copy-versions of branded medicines with the identical active ingredient and dosage forms. Super generics or value-added generics are improved versions of already established drugs that promise better efficacy or less side effects. Biosimilars are essentially generic versions of biologic drugs, which are highly complex molecules made from a living organism.

𝐈𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧, generic drugs are used in many therapeutic areas, including cardiovascular diseases, oncology, diabetes, neurology, and infectious diseases. The cardiovascular segment accounts for a significant share owing to the widespread incidence of heart diseases across the globe. Additionally, oncology is another major growth driver, as cancer becomes more prevalent and branded oncology drugs are more expensive.

If we talk about the distribution channels, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Retail pharmacies are the market's major players, thanks to their ubiquitous presence and ease of access for patients. Online pharmacies are on the rise, particularly in urban regions, as home delivery becomes a common appointment and prices remain competitive.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐋𝐢𝐧𝐤 𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:-https://www.stellarmr.com/report/enquire_now/Generic-Drug-Market/1638

𝐂𝐨𝐮𝐧𝐭𝐫𝐲-𝐋𝐞𝐯𝐞𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

The United States has a developed generic drug market, which makes up about 84 percent of prescriptions filled. Supportive regulatory frameworks and initiatives to curb healthcare spending are driving the high adoption rate. Similarly, for example, the Hatch-Waxman Act makes the approval pathway for generic drugs less difficult, creating additional market access.

The German generic drug market is strong, and the drug market as a whole has a significant focus on overall cost containment within health care. This environment has been conducive for the usage of generic drugs, mainly due to a system of reference pricing and mandatory substitution. Patients in Germany receive medication of high generic quality, which significantly conserves resources for the healthcare system.

The generic market in China is growing rapidly, fuelled by healthcare reform and the government's commitment to affordable healthcare. QCE offers reassurance to consumers as they can rest assured that domestically manufactured generic drugs meet international quality standards.

India is the world leader in pharmaceutical medicines, exporting nearly USD 20 billion worth of generic medicines in the 2019-20 financial year. (Idhiraj and Pal, 2008) The well-established pharmaceutical manufacturing industry in the country with low overheads and manufacturing costs have turned the country into a significant generics supplier for global markets.

It has grown substantially since then due to pro-access policies from the government. The National Policy of Generic Medicines also encourages the utilization of generics through awareness programs as well as manufacturers incentives, and the implementation of such policy has enhanced the market penetration of generics.

𝐅𝐨𝐫 𝐚 𝐪𝐮𝐢𝐜𝐤 𝐬𝐮𝐦𝐦𝐚𝐫𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐜𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞:-https://www.stellarmr.com/report/req_sample/Generic-Drug-Market/1638

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐨𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

The industry for generic drugs is competitive, with several companies undertaking strategic measures and product investments to maintain their share of the market.

Israel-based Teva Pharmaceutical Industries Ltd. is one of the biggest players in the generic drug market. The company has a basket of generic drugs in several therapeutic areas and is growing through acquisitions and new launches.

The former Mylan N.V., now owned by Viatris Inc., has a vast international business selling generic drugs. The very large product portfolio and the emphasis on customer specific complex generics has established the company solidly in the marketplace.

Novartis International AG's Sandoz unit is a major player in the generic drug industry. Sandoz focused on biosimilars and complex generics, using R&D to launch new products.

Indian company Sun Pharmaceutical Industries Ltd. has made a mark in the generic pharmaceuticals industry. The purpose-built acquisitions and specialization in generics have allowed the company to expand its market presence.

In 2020, the merger of Mylan N.V. with Upjohn, a division of Pfizer that produces off-patent drugs, created Viatris Inc. This initiative is designed to combine the scale and capabilities of both companies to improve the global availability of high-quality low-cost generic medicines.

𝐆𝐞𝐭 𝐭𝐨 𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞 𝐀𝐛𝐨𝐮𝐭 𝐓𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲:https://www.stellarmr.com/report/Generic-Drug-Market/1638

𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞 𝐂𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧

The global generic drug market is anticipated to witness significant growth in the coming years due to the rising need for affordable healthcare options along with the patent expiration of drugs. This makes the market highly lucrative for market players, thrived with government-friendly policies and efficient treatments. With health sectors across the globe exerting effort to seek the lost balance between quality and cost, generic drugs will always be a prominent part in progressing towards overall health.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

♦ Healthcare Quality Management Software market https://www.stellarmr.com/report/Healthcare-Quality-Management-Software-Market/1418

♦ Anti-Acne Cosmetics Market https://www.stellarmr.com/report/Anti-Acne-Cosmetics-Market/487

♦ Anemia Treatment Market https://www.stellarmr.com/report/Anemia-Treatment-Market/496

♦ Analgesics Market https://www.stellarmr.com/report/Analgesics-Market/498

♦ 5G in Healthcare Market https://www.stellarmr.com/report/5G-in-Healthcare-Market/517

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐒𝐭𝐞𝐥𝐥𝐚𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
S.no.8, h.no. 4-8 Pl.7/4, Kothrud,
Pinnac Memories Fl. No. 3, Kothrud, Pune,
Pune, Maharashtra, 411029
sales@stellarmr.com

𝐀𝐛𝐨𝐮𝐭 𝐒𝐭𝐞𝐥𝐥𝐚𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

This release was published on openPR.